Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
نویسندگان
چکیده
منابع مشابه
Anti-CD20 antibody therapy for B-cell lymphomas.
n engl j med 366;21 nejm.org may 24, 2012 2008 This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented...
متن کاملAnti-CD20 antibody therapy and susceptibility to Pneumocystis pneumonia.
Anti-CD20 antibody therapy has been a useful medication for managing non-Hodgkin's lymphoma as well as autoimmune diseases characterized by autoantibody generation. CD20 is expressed during most developmental stages of B lymphocytes; thus, CD20 depletion leads to B-lymphocyte deficiency. As the drug has become more widely used, there has been an increase in the number of case reports of patient...
متن کاملOfatumumab: a novel monoclonal anti-CD20 antibody
Ofatumumab, a novel humanized monoclonal anti-CD20 antibody, was recently approved by the FDA for the treatment of fludarabine and alemtuzumab refractory chronic lymphocytic leukemia (CLL). Ofatumumab effectively induces complement-dependent cytotoxicity (CDC) in vitro, and recent studies demonstrated that ofatumumab also effectively mediates antibody-dependent cellular cytotoxicity (ADCC). Pha...
متن کاملConstruction and cloning of a recombinant expression vector containing human Cd20 Gene for antibody therapy in Non-Hodgkin Lymphoma
ABSTRACT Introduction: Non-Hodgkin lymphoma (NHL) is a cancer that starts in lymphocytes. The main treatment for NHL is chemotherapy and radiation. Today immunotherapy is a promising therapeutic approach in the treatment of a variety cancers which is high specific unlike previous methods. Antibodies do not penetrate effectively into tumore tissues because of their large size. Whe...
متن کاملAbsolute lymphocyte count as a predictive factor for response to monoclonal anti-CD20 antibody therapy.
Over recent years, anti-CD20 monoclonal antibodies (Mab) have become available for the treatment of B-cell non-Hodgkin’s lymphoma (NHL). Despite a relatively high response rate, a few patients appear to remain resistant to treatment. In order to identify patients in whom rituximab could be beneficial, we evaluated the influence of various clinical and laboratory parameters on response to immuno...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Neurology
سال: 2018
ISSN: 0340-5354,1432-1459
DOI: 10.1007/s00415-018-8812-0